ACCESS DB # 157366

FOR OFFICIAL USE ONLY

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Jeffrey E. Russel Examiner #: 62785 Date: 6-23-2005

Art Unit: 1654 Phone Number: 2-0969 Serial Number: 10/049,748

Location (Bldg/Room#): REM 3D19 (Mailbox #): 3C18 Results Format Preferred (circle): (PAPER) DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Melanocortin Metallopeptide Constructs, Combinatorial Libraries, And Applications

Inventors (please provide full names): S. Sharma, Y. Sui, Y. Wei, H. Cai

Earliest Priority Date: 6-15-2002

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search the following partial sequences in STN:

(1) (~~Phe~~ Phe / Tyr / Trp) - (Lys / Arg / His) - Cys - (Phe / Tyr / Trp) ; (2) Cys - (Phe / Tyr / Trp) - (Lys / Arg / His) - (Phe / Tyr / Trp) ;

(3) (Lys / Arg / His) - (Lys / Arg / His) - (Phe / Tyr / Trp) - Cys ; (4) (Gly Ala / Leu Ile / Val Phe / Trp) - (Phe / Tyr / Trp) - Cys - (Phe / Tyr / Trp).

Please require any sequence to have 8 or fewer residues.

Please exclude from the answer set any reference with S. Sharma as an author or inventor.

If necessary, please use the keywords Rhenium/Re or Technetium/Tc to narrow any hits.

Thank you. JER

****

STAFF USE ONLY

Searcher: _____

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: _____

Searcher Prep & Review Time: _____

Online Time: _____

Type of Search

_____ NA Sequence (#)

_____ AA Sequence (#)

_____ Structure (#)

_____ Bibliographic

_____ Litigation

_____ Fulltext

_____ Other

Vendors and cost where applicable

_____ STN _____ Dialog

_____ Questel/Orbit _____ Lexis/Nexis

_____ Westlaw _____ WWW/Internet

____ In-house sequence systems

___ Commercial ___ Oligomer ____ Score/Length

___ Interference ___ SPDI ____ Encode/Transl

_____ Other (specify)

Russel 10/049718

```
=> del his y

=> fil medl,biosis,embase,caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY      SESSION
FULL ESTIMATED COST                                    1.72       359.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY      SESSION
CA SUBSCRIBER PRICE                                    0.00        -1.46

FILE 'MEDLINE' ENTERED AT 11:31:17 ON 30 JUN 2005

FILE 'BIOSIS' ENTERED AT 11:31:17 ON 30 JUN 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:31:17 ON 30 JUN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 11:31:17 ON 30 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> s sharma s?/au;s sli y?/au or li y?/au;s wei y?/au;s cai h?/au
L1          4144 FILE MEDLINE
L2          6570 FILE BIOSIS
L3          3632 FILE EMBASE
L4          6398 FILE CAPLUS

TOTAL FOR ALL FILES
L5         20744 SHARMA S?/AU


L6         10006 FILE MEDLINE
L7         11498 FILE BIOSIS
L8          7357 FILE EMBASE
L9         36927 FILE CAPLUS
```

7-1-2005

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUN 2005 HIGHEST RN 853295-05-3
DICTIONARY FILE UPDATES: 29 JUN 2005 HIGHEST RN 853295-05-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

```
=> s [fyw][krh]c[fyw]/sqsp
L1        20268 [FYW][KRH]C[FYW]/SQSP

=> s c[fyw][krh][fyw]/sqsp
L2        21224 C[FYW][KRH][FYW]/SQSP

=> s [krh][krh][fyw]c/sqsp
L3        37510 [KRH][KRH][FYW]C/SQSP

=> s [galivfw][fyw]c[fyw]/sqsp
L4        81929 [GALIVFW][FYW]C[FYW]/SQSP

=> s 4-8/sql
L5       310374 4-8/SQL

=> s (l1 or l2 or l3 or l4) and l5
L6          694 (L1 OR L2 OR L3 OR L4) AND L5

=> s rhenium/cn;s technetium/cn
L7            1 RHENIUM/CN


L8            1 TECHNETIUM/CN

=> fil hcap;s l6
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY     SESSION
FULL ESTIMATED COST                          125.09      125.94
```

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

FILE 'HCAPLUS' ENTERED AT 11:10:02 ON 30 JUN 2005

FILE COVERS 1907 - 30 Jun 2005 VOL 143 ISS 1
FILE LAST UPDATED: 29 Jun 2005 (20050629/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
L9          221 L6

=> s sharma s?/au
L10        6398 SHARMA S?/AU

=> s l9 not l10
L11         214 L9 NOT L10

=> s l11 and (l7 or l8 or rhenium or technetium)
          17090 L7
           3932 L8
          33334 RHENIUM
              8 RHENIUMS
          33334 RHENIUM
                  (RHENIUM OR RHENIUMS)
          16522 TECHNETIUM
              1 TECHNETIUMS
          16522 TECHNETIUM
                  (TECHNETIUM OR TECHNETIUMS)
L12           6 L11 AND (L7 OR L8 OR RHENIUM OR TECHNETIUM)

=> d 1-6 ibib abs hitstr

L12 ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:501605  HCAPLUS
DOCUMENT NUMBER:          142:172648
TITLE:                    Optimization of biomolecules labelling with
                          rhenium-188 using direct and indirect methods
AUTHOR(S):                de Castiglia, S. G.; Crudo, J.; Obenaus, E.; Edreira,
                          M.; D'Orio, E.
CORPORATE SOURCE:         Centro Atomico Ezeiza Comision, Nacional de Energia
                          Atomica, Buenos Aires, Argent.
SOURCE:                   International Atomic Energy Agency, [Technical
                          Document], IAEA-TECDOC (2003), IAEA-TECDOC-1359,
```

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Labeling Techniques of Biomolecules for Targeted Radiotherapy, 31-44
CODEN: IAEIE2; ISSN: 1011-4289
DOCUMENT TYPE: Report
LANGUAGE: English

AB Active tetrafluorophenol-MAG3-188Re ester, obtained from S-benzoyl-MAG3, is useful for the preconjugate radiolabeling of a variety of biomols. The authors report the optimization of polyclonal IgG labeling by 188Re using S-benzoyl-MAG3 as a model for labeling monoclonal antibodies. They examined the in vitro stability of the labeled protein and its localization and excretion in mice with induced focal inflammation. Stability in serum was greater than 85.5% after 24 h. Biodistribution and imaging studies following administration to mice showed mainly renal and hepatic excretion and high IT/NT ratios (4.5 and 4.6) at 24 and 48 h, resp. Likewise, the monoclonal antibody 14f7 was labeled with 188Re using this technique and the same controls were carried out with the labeled protein but in mice bearing a tumor. Tumor uptake increased in 24 h from 3.9 to 8.8% ID/gr and stood constant since then. On the other hand, a direct labeling method was studied and lanreotide-188Re was obtained with almost 100% of radiochem. purity. Lanreotide was also labeled with 111In and 90Y through DOTA chelator, showing mainly renal excretion when administered to rats. Finally DOTA-TOC was labeled with 90Y and data showed that a lower mass is needed in order to label it with the same amount of activity than DOTA-lanreotide.

IT **189758-25-6P**, 90Y-DOTA-TOC
RL: PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(biomol. labeling with **rhenium**-188, indium-111, and yttrium-90, stability in saline and blood serum, and biodistribution in animals)

RN 189758-25-6 HCAPLUS

CN Yttrium-90Y, [N-[[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl-κO]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2→7)-disulfidato(3-)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-B

IT **204318-14-9**, DOTA-TOC
RL: RCT (Reactant); RACT (Reactant or reagent)
(biomol. labeling with **rhenium**-188, indium-111, and yttrium-90, stability in saline and blood serum, and biodistribution in animals)

RN 204318-14-9 HCAPLUS

CN L-Cysteinamide, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:287861 HCAPLUS
DOCUMENT NUMBER: 140:320038
TITLE: Chimeric and humanized anti-granulocyte antibodies, immunoconjugates and labeled antibodies for diagnosis and treatment of malignancy, infection and inflammation
INVENTOR(S): Goldenberg, David M.; Hansen, Hans; Leung, Shui-on
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; Mccall, John Douglas
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029093	A2	20040408	WO 2003-GB4229	20030930
WO 2004029093	A3	20040603		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1546204	A2	20050629	EP 2003-751001	20030930

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-414341P	P	20020930
	WO 2003-GB4229	W	20030930

AB The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments that bind NCA90 and NCA95 antigens. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocyte related disorders and diseases, such as leukemia.

IT **676600-52-5**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric and humanized anti-granulocyte antibodies, immunoconjugates and labeled antibodies for diagnosis and treatment of malignancy, infection and inflammation)

RN 676600-52-5 HCAPLUS

CN D-Lysinamide, N-[[(aminothioxomethyl)hydrazono]acetyl]-L-cysteinyl-D-phenylalanyl-N6-[N-[4-[[2-(1H-imidazol-4-yl)ethyl]amino]-1,4-dioxobutyl]glycyl]-D-lysyl-D-tyrosyl-N6-[N-[4-[[2-(1H-imidazol-4-yl)ethyl]amino]-1,4-dioxobutyl]glycyl]-D-lysyl-N6-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



IT **7440-15-5**, **Rhenium**, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric and humanized anti-granulocyte antibodies, immunoconjugates and labeled antibodies for diagnosis and treatment of malignancy, infection and inflammation)
RN 7440-15-5 HCAPLUS
CN Rhenium (8CI, 9CI) (CA INDEX NAME)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Re

L12 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:867941 HCAPLUS
DOCUMENT NUMBER: 139:369669
TITLE: Benzothienyl analogue of somatostatin, selective for certain somatostatin receptors
INVENTOR(S): De Jong, Marion; Maecke, Helmut Robert; Ginj, Mihaela; Krenning, Eric Paul; Reubi, Jean Claude
PATENT ASSIGNEE(S): Biosynthema, Inc., USA
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1358890	A1	20031105	EP 2002-76757	20020503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2003092744	A2	20031113	WO 2003-EP4847	20030502
WO 2003092744	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1501554	A2	20050202	EP 2003-722601	20030502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: EP 2002-76757 A 20020503
WO 2003-EP4847 W 20030502
OTHER SOURCE(S): MARPAT 139:369669

AB The invention relates to a peptide compound having an improved binding affinity to somatostatin receptors, comprising a peptide and a chelating group covalently linked to a free amino group of said peptide , wherein said peptide is or comprises a somatostatin analog carrying a 3-benzothienylalanine residue in its 3-position. The invention further relates to said peptide compound labeled with a detectable element or with a therapeutic radionuclide, as well as to a diagnostic method and to a method for the therapeutic treatment of tumors, by using the labeled compds.

IT **204318-14-9D**, Y-90 labeled conjugates **209277-09-8D**, Y-90 labeled conjugates
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(somatostatin analog conjugates with diagnostic or therapeutic agents)
RN 204318-14-9 HCAPLUS
CN L-Cysteinamide, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-

threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 209277-09-8 HCAPLUS

CN L-Cysteinamide, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:836381 HCAPLUS
DOCUMENT NUMBER: 139:341719
TITLE: Use of bi-specific antibodies for pre-targeting diagnosis and therapy

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

INVENTOR(S): Goldenberg, David M.; Hansen, Hans J.; Leung, Shui-on; McBride, William J.; Qu, Zhengxing
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 59 pp., Cont.-in-part of U.S. Ser. No. 823,746.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 16
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003198595	A1	20031023	US 2002-150654	20020517
US 2002006379	A1	20020117	US 2001-823746	20010403
CA 2486307	AA	20031127	CA 2003-2486307	20030516
WO 2003097105	A1	20031127	WO 2003-GB2110	20030516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1506018	A1	20050216	EP 2003-725404	20030516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003010088	A	20050405	BR 2003-10088	20030516
US 2005002945	A1	20050106	US 2004-776470	20040211

PRIORITY APPLN. INFO.:

US 1998-90142P	P	19980622
US 1998-104156P	P	19981014
US 1999-382186	A2	19990823
US 2001-823746	A2	20010403
US 1999-337756	A2	19990622
US 2002-150654	A	20020517
WO 2003-GB2110	W	20030516

AB The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

IT **615535-87-0D**, radiolabeled
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bi-specific antibodies for pre-targeting diagnosis and therapy)

RN 615535-87-0 HCAPLUS

CN L-Lysinamide, N-[[(aminothioxomethyl)hydrazono]acetyl]-L-cysteinyl-L-phenylalanyl-N6-[N-[4-[[2-(1H-imidazol-4-yl)ethyl]amino]-1,4-dioxobutyl]glycyl]-L-lysyl-D-tyrosyl-N6-[N-[4-[[2-(1H-imidazol-4-yl)ethyl]amino]-1,4-dioxobutyl]glycyl]-L-lysyl-N6-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



L12 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:754237 HCAPLUS
DOCUMENT NUMBER: 137:299886
TITLE: Serum albumin-binding moieties
INVENTOR(S): Sato, Aaron K.; Ley, Arthur C.; Cohen, Edward H.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

PATENT ASSIGNEE(S): Dyax Corp., USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002076489	A1	20021003	WO 2002-US7271		20020308
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2440582	AA	20021003	CA 2002-2440582		20020308
US 2003069395	A1	20030410	US 2002-94401		20020308
EP 1377306	A1	20040107	EP 2002-753771		20020308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004535373	T2	20041125	JP 2002-575002		20020308
PRIORITY APPLN. INFO.:			US 2001-331352P	P	20010309
			US 2001-292975P	P	20010523
			WO 2002-US7271	W	20020308

OTHER SOURCE(S): MARPAT 137:299886

AB Compns. comprising non-naturally occurring serum albumin-binding moieties are described, together with methods of use thereof, e.g., for detecting or isolating serum albumin mols. in a solution, for blood circulation imaging, and for linking therapeutics or other mols. to albumin. Preferred serum albumin-binding peptides having a high affinity for human serum albumin are particularly disclosed.

IT **7440-26-8**, **Technetium**, biological studies
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide conjugates; serum albumin-binding peptides for imaging and drug delivery)
RN 7440-26-8 HCAPLUS
CN Technetium (8CI, 9CI) (CA INDEX NAME)

Tc

IT **463968-26-5**
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(serum albumin-binding peptides for imaging and drug delivery)
RN 463968-26-5 HCAPLUS
CN L-Cysteine, L-cysteinyl-L-tryptophyl-L-histidyl-L-phenylalanyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:73387 HCAPLUS
DOCUMENT NUMBER: 134:127880
TITLE: Method to enhance tissue accumulation of radiolabeled compounds
INVENTOR(S): Woltering, Eugene A.; Espenan, Gregory D.
PATENT ASSIGNEE(S): Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, USA
SOURCE: U.S., 46 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6180082	B1	20010130	US 1998-198562		19981123
US 6630123	B1	20031007	US 2000-664456		20000918
PRIORITY APPLN. INFO.:			US 1997-160087P	P	19971124
			US 1998-198562	A1	19981123

AB Administration of a radioisotopic compound by infusion over a period of time greater than two hours, preferably greater than twelve hours, greatly increases the maximum radioactivity that accumulates in the target cell. Increasing tissue accumulation and retention of radiolabeled compds. improves their therapeutic and diagnostic value. The efficacy of the administration of the radiolabeled compound can be increased about five times higher than prior bolus injection or short infusion methods. This method enhances the tumor to background ratio by increasing the actual radioligand accumulated inside the target cells. This technique works for any radiolabeled compound whose cellular uptake is limited by a cellular process of either binding to a cellular receptor or to a transport protein. Once the radiolabeled compound is bound and internalized, the ability of an unlabeled compound to compete with the radioligand is markedly decreased. The primary factor governing residence time after internalization is the phys. half-life of the radioisotope, not biol. half-life. Preliminary results of clin. trial with 111In-pentetreotide

infusions are presented.

IT **189758-25-6 321999-23-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for enhancing tumor and angiogenic tissue accumulation of radiopharmaceuticals)

RN 189758-25-6 HCAPLUS

CN Yttrium-90Y, [N-[[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl-κO]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2→7)-disulfidato(3-)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-B

RN 321999-23-9 HCAPLUS
CN Yttrium-86Y, [N-[[4,7-bis[(carboxy-κO)methyl]-10-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10] acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2→7)-disulfidato(3-)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-B

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

```
=> dis his

     (FILE 'HOME' ENTERED AT 11:06:12 ON 30 JUN 2005)

     FILE 'REGISTRY' ENTERED AT 11:07:56 ON 30 JUN 2005

     FILE 'REGISTRY' ENTERED AT 11:07:58 ON 30 JUN 2005
L1         20268 S [FYW][KRH]C[FYW]/SQSP
L2         21224 S C[FYW][KRH][FYW]/SQSP
L3         37510 S [KRH][KRH][FYW]C/SQSP
L4         81929 S [GALIVFW][FYW]C[FYW]/SQSP
L5        310374 S 4-8/SQL
L6           694 S (L1 OR L2 OR L3 OR L4) AND L5
L7             1 S RHENIUM/CN
L8             1 S TECHNETIUM/CN

     FILE 'HCAPLUS' ENTERED AT 11:10:02 ON 30 JUN 2005
L9           221 S L6
L10         6398 S SHARMA S?/AU
L11          214 S L9 NOT L10
L12            6 S L11 AND (L7 OR L8 OR RHENIUM OR TECHNETIUM)

=> save l9 russel718_part1
RUSSEL718_PART1 IS NOT A VALID SAVED NAME
Enter the name you wish to use for the saved query,
answer set, or L-number list.  The name must:
  1. Begin with a letter,
  2. Have 1-12 characters,
  3. Contain only letters (A-Z) and numbers (0-9),
  4. End with /Q for a query (search profile,
     structure, or screen set), /A for an answer
     set, or /L for an L-number list.
  5. Not already be in use as a saved name,
  6. Not be END, SAV, SAVE, SAVED
  7. Not have the form of an L-number (Lnnn).
ENTER NAME OR (END):end

=> save l9 russel718_pt1/a
RUSSEL718_PT1/A IS NOT A VALID SAVED NAME
Enter the name you wish to use for the saved query,
answer set, or L-number list.  The name must:
  1. Begin with a letter,
  2. Have 1-12 characters,
  3. Contain only letters (A-Z) and numbers (0-9),
  4. End with /Q for a query (search profile,
     structure, or screen set), /A for an answer
     set, or /L for an L-number list.
  5. Not already be in use as a saved name,
  6. Not be END, SAV, SAVE, SAVED
  7. Not have the form of an L-number (Lnnn).
ENTER NAME OR (END):
```

TOTAL FOR ALL FILES
L10 65788 SLI Y?/AU OR LI Y?/AU

L11 1108 FILE MEDLINE
L12 1294 FILE BIOSIS
L13 875 FILE EMBASE
L14 4461 FILE CAPLUS

TOTAL FOR ALL FILES
L15 7738 WEI Y?/AU

L16 414 FILE MEDLINE
L17 517 FILE BIOSIS
L18 305 FILE EMBASE
L19 1334 FILE CAPLUS

TOTAL FOR ALL FILES
L20 2570 CAI H?/AU

=> s l5 and l10 and l15 and l20
L21 0 FILE MEDLINE
L22 0 FILE BIOSIS
L23 0 FILE EMBASE
L24 0 FILE CAPLUS

TOTAL FOR ALL FILES
L25 0 L5 AND L10 AND L15 AND L20

=> s (l5 or l10 or l15 or l20) and (melanocortin or metallopeptide)
L26 14 FILE MEDLINE
L27 26 FILE BIOSIS
L28 11 FILE EMBASE
L29 39 FILE CAPLUS

TOTAL FOR ALL FILES
L30 90 (L5 OR L10 OR L15 OR L20) AND (MELANOCORTIN OR METALLOPEPTIDE)

=> s l30 and combinat? librar?
L31 0 FILE MEDLINE
L32 0 FILE BIOSIS
L33 0 FILE EMBASE
L34 3 FILE CAPLUS

TOTAL FOR ALL FILES
L35 3 L30 AND COMBINAT? LIBRAR?

=> d 1-3 ibib abs

L35 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:380441 CAPLUS
DOCUMENT NUMBER: 135:519
TITLE: Opioid **metallopeptide** compositions and methods
INVENTOR(S): **Sharma, Shubh D.; Wei, Yang; Cai, Hui-Zhi**
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 52 pp.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036006	A1	20010525	WO 2000-US31797	20001117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-166582P P 19991119

AB **Metallopeptides** and **metallopeptide combinatorial libraries** specific for opioids receptors are provided, for use in biol., pharmaceutical and related applications. The **metallopeptides** and **combinatorial libraries** are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:137478 CAPLUS
DOCUMENT NUMBER: 134:188233
TITLE: **Melanocortin metallopeptide** constructs, **combinatorial libraries** , and applications
INVENTOR(S): **Sharma, Shubh D.**; Shi, Yi-Qun; Yang, Wei; **Cai, Hui-Zhi**
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001013112	A1	20010222	WO 2000-US16396	20000615

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2379647	AA	20010222	CA 2000-2379647	20000615

EP 1208377	A1	20020529	EP 2000-944681		20000615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
JP 2004519410	T2	20040702	JP 2001-517163		20000615
PRIORITY APPLN. INFO.:			US 1999-148994P	P	19990812
			WO 2000-US16396	W	20000615

OTHER SOURCE(S): MARPAT 134:188233

AB **Metallopeptides** and **metallopeptide combinatorial libraries** specific for **melanocortin** receptors are provided, for use in biol., pharmaceutical and related applications. The **metallopeptides** and **combinatorial libraries** are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:421334 CAPLUS

DOCUMENT NUMBER: 133:55661

TITLE: **Metallopeptide combinatorial libraries** synthesis and applications

INVENTOR(S): **Sharma, Shubh D.**; Shi, Yiqun

PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA

SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000036136	A1	20000622	WO 1999-US29743		19991214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2353072	AA	20000622	CA 1999-2353072		19991214
EP 1141375	A1	20011010	EP 1999-964263		19991214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002536295	T2	20021029	JP 2000-588384		19991214
AU 760257	B2	20030508	AU 2000-20541		19991214
US 2002012948	A1	20020131	US 2001-883069		20010614
PRIORITY APPLN. INFO.:			US 1998-112235P	P	19981214
			US 1995-476652	A	19950607
			US 1996-660697	A	19960605
			WO 1999-US29743	W	19991214

AB **Metallopeptide combinatorial libraries** and methods of making libraries and **metallopeptides** are provided for use in biol., pharmaceutical and related applications. The **combinatorial libraries** are made of peptides,

peptidomimetics and peptide-like constructs, and include a metal ion-binding region thereof which includes at least one orthogonal sulfur-protecting group, in which the peptide, peptidomimetic or construct is conformationally fixed on deprotection of the sulfur and complexation of the metal ion-binding region with a metal ion. Methods of synthesis of these **metallopeptides** are described. Thereafter the library members may be screened to select those with the desired specificity and affinity.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT